These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15042691)

  • 21. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y; Seto T; Nishiwaki Y; Ohe Y; Yamada Y; Takeda K; Saijo N; Hotta T
    Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG; Natale JJ
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
    Rose S; Ali Y; Maffei B; Saidi P
    Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
    [No Abstract]   [Full Text] [Related]  

  • 29. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    VanAudenrode M
    J Natl Cancer Inst; 2003 May; 95(10):761-2; author reply 762-3. PubMed ID: 12759400
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.
    Van Belle S; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Aerts JG
    Curr Med Res Opin; 2012 Jul; 28(7):1079-87. PubMed ID: 22642867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W
    Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.